

# Lisa Pickering

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6022457/publications.pdf>

Version: 2024-02-01

22  
papers

9,682  
citations

623188

14  
h-index

794141

19  
g-index

24  
all docs

24  
docs citations

24  
times ranked

16623  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre. <i>Journal of Clinical Urology</i> , 2023, 16, 293-302.	0.1	2
2	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. <i>Lancet, The</i> , 2022, 399, 905-907.	6.3	60
3	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. <i>Cancer Cell</i> , 2022, 40, 114-116.	7.7	50
4	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102.	3.4	30
5	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, A012-A012.	0.4	0
6	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, PR002-PR002.	0.4	0
7	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-“Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	3.2	14
8	Selection of metastasis competent subclones in the tumour interior. <i>Nature Ecology and Evolution</i> , 2021, 5, 1033-1045.	3.4	50
9	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
10	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
11	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51
12	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 343-354.	1.1	0
13	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. <i>Cell</i> , 2018, 173, 595-610.e11.	13.5	472
14	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12.	13.5	609
15	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
16	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , 2017, 80, 55-62.	1.3	18
17	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Translational Oncology</i> , 2017, 10, 679-685.	1.7	9
18	Pazopanib-Induced Alopecia, an Underestimated Toxicity?. <i>Frontiers in Oncology</i> , 2015, 5, 112.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336.	5.8	100
20	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948.	0.9	141
21	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233.	9.4	1,103
22	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892.	13.9	6,769